The NICHE-2 study offered neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer patients, resulting in a major pathologic response in 95% of patients and 67% pCR. In discussion with the lead author, Dr. Myriam Chalabi – Medical Oncologist at the Netherlands Cancer Institute.
![The NICHE-2 Study Discussion with Dr. Myriam Chalabi - Onc Brothers](https://oncbrothers.com/wp-content/uploads/2023/01/Screenshot-2023-01-16-065642-1200x513.png)